Outcome of Surgical Treatment of Giant Cell Tumors of Bone Around the Knee Joint for Extended Curettage or Segmental Resection: A Retrospective Study

膝关节周围骨巨细胞瘤手术治疗的疗效:刮除术或节段切除术的回顾性研究

阅读:1

Abstract

Background Giant cell tumors (GCTs) of bone around the knee are locally aggressive benign neoplasms with a tendency for recurrence and functional compromise. Surgical options include extended curettage (EC), often combined with adjuvants and internal fixation (sandwich technique), or segmental resection (SR) with megaprosthesis reconstruction. The optimal approach remains debated. This study compares oncological and functional outcomes between these two surgical strategies in a cohort of 65 patients. Methods A retrospective analysis was conducted at the Department of Orthopaedics, Indira Gandhi Institute of Medical Sciences, Patna, over six years. Patients with biopsy-confirmed GCTs around the knee who underwent EC or SR were included. Outcomes assessed included local recurrence, recurrence-free survival (RFS), Musculoskeletal Tumor Society (MSTS) scores, operative time, blood loss, hospital stay, and postoperative complications. Results Of the 65 patients (EC: 48; SR: 17), local recurrence was noted in 12.5% of the EC group and 5.9% of the SR group (p=0.762). For Grade II tumors, recurrence occurred in 4.2% of EC cases and none in SR; for Grade III tumors, recurrence rates were 8.3% (EC) and 5.9% (SR). At three years, RFS was 87.5% for EC and 94.1% for SR (p=0.604). SR involved longer surgeries (172.7 ± 36.3 vs. 119.2 ± 23.8 min, p<0.001), greater blood loss (656.8 ± 155.6 vs. 319.6 ± 127.9 mL, p<0.001), and longer hospital stays. EC demonstrated superior functional outcomes (MSTS: 25.5 ± 3.2 vs. 22.1 ± 3.8, p=0.007). Complication rates were higher in SR (35.3%) compared to EC (20.8%), though not statistically significant (p=0.268). Conclusion EC offers superior functional outcomes with a non-significant trend toward higher recurrence, whereas SR provides better local control at the cost of greater surgical morbidity. These findings suggest that patient selection should consider tumor grade, extent, and individual functional priorities. Prospective studies are needed to refine treatment algorithms and optimize outcomes.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。